PTCOG Ocular Survey – Perspective on Ocular Particle Therapy: Current Practices and Emerging Trends

Purpose: To overview the status and trends in the current rapidly evolving field of ocular particle therapy (OPT). Materials and Methods: The Particle Therapy Co-Operative Group Ocular Subcommittee developed an online survey, including 127 questions, made available to treatment centers worldwide, between April 2022 and January 2024. The survey covered a broad range of topics from general program organization and beamline description, to diagnoses and patient numbers treated, treatment planning and set-up, quality assurance techniques, as well as insights into anticipated future developments. Results: Twenty facilities offered OPT by the end of 2023: 3 in Asia, 9 in Europe, and 8 in the USA. Combined, they treated, on average, 1800 patients per year, with uveal melanoma being the most common indication. The vast majority of treatments continue to be delivered on dedicated horizontal beamlines, both high (>120 Mev) and low (